In the direct comparison of [68Ga]Ga-RM2 and [68Ga]Ga-PSMA-11 on PET/CT in seven patients with biochemically recurring prostate cancer, shown in Figure 7, the heterogeneity of GRPR and PSMA expression was evident, highlighting the benefit of using both targets in a complementary fashion to increase diagnostic accuracy [103]. This evidence concerns the gene FOLH1 and prostate carcinoma.